Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yann Godet

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Experimental Hematology & Oncology|March 4, 2016
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignanciesClémentine Gamonet, Elodie Bole-Richard, Aurélia Delherme, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2016
Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic CellsJeanne Galaine, Guillaume Kellermann, Yves Guillaume, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumorMagalie Dosset, Yann Godet, Charline Vauchy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2012
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy responseYann Godet, Elizabeth Fabre, Magalie Dosset, et al.
Oncotarget|April 22, 2017
Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic miceLaurie Rangan, Jeanne Galaine, Romain Boidot, et al.
Cell Reports. Medicine|June 21, 2025
UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunityCaroline Laheurte, Laura Boullerot, Babacar Ndao, et al.
Oncoimmunology|February 5, 2019
Circulating NKp46<sup>+</sup> Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung CancerEmilie Picard, Yann Godet, Caroline Laheurte, et al.
Cancer Immunology Research|May 31, 2024
Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T CellsMaxime Fredon, Margaux Poussard, Sabeha Biichlé, et al.
Cancer Immunology Research|October 20, 2025
Targeting SALL4 with an HLA Class I-Restricted TCR for Cancer ImmunotherapyMyriam Ben Khelil, Maxime Fredon, Nawfel Adib, et al.
Cancer Research|May 20, 2016
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell ImmunityLaurent Beziaud, Laura Mansi, Patrice Ravel, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Experimental Hematology & Oncology|March 4, 2016
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignanciesClémentine Gamonet, Elodie Bole-Richard, Aurélia Delherme, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2016
Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic CellsJeanne Galaine, Guillaume Kellermann, Yves Guillaume, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumorMagalie Dosset, Yann Godet, Charline Vauchy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2012
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy responseYann Godet, Elizabeth Fabre, Magalie Dosset, et al.
Oncotarget|April 22, 2017
Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic miceLaurie Rangan, Jeanne Galaine, Romain Boidot, et al.
Cell Reports. Medicine|June 21, 2025
UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunityCaroline Laheurte, Laura Boullerot, Babacar Ndao, et al.
Oncoimmunology|February 5, 2019
Circulating NKp46<sup>+</sup> Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung CancerEmilie Picard, Yann Godet, Caroline Laheurte, et al.
Cancer Immunology Research|May 31, 2024
Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T CellsMaxime Fredon, Margaux Poussard, Sabeha Biichlé, et al.
Cancer Immunology Research|October 20, 2025
Targeting SALL4 with an HLA Class I-Restricted TCR for Cancer ImmunotherapyMyriam Ben Khelil, Maxime Fredon, Nawfel Adib, et al.
Cancer Research|May 20, 2016
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell ImmunityLaurent Beziaud, Laura Mansi, Patrice Ravel, et al.
Pageof 6